Alexandre Andre Balieiro Anstacio Da Costa, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystadenocarcinoma, Serous | 5 | 2017 | 473 | 1.030 |
Why?
|
| Endometrial Neoplasms | 7 | 2020 | 1365 | 0.940 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 4849 | 0.870 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 217 | 0.790 |
Why?
|
| Neoplasm, Residual | 4 | 2022 | 1008 | 0.770 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 1113 | 0.720 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2024 | 2020 | 0.690 |
Why?
|
| Platinum Compounds | 1 | 2019 | 95 | 0.630 |
Why?
|
| Cyclin E | 1 | 2019 | 155 | 0.630 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2019 | 101 | 0.630 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 5304 | 0.620 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 106 | 0.550 |
Why?
|
| Lymph Node Excision | 5 | 2022 | 1269 | 0.550 |
Why?
|
| Lymphatic Metastasis | 7 | 2022 | 2913 | 0.530 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2021 | 732 | 0.520 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 1661 | 0.520 |
Why?
|
| Hysterectomy | 4 | 2021 | 856 | 0.500 |
Why?
|
| Oncogene Proteins | 1 | 2019 | 718 | 0.490 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2014 | 26 | 0.470 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 797 | 0.450 |
Why?
|
| Platinum | 1 | 2015 | 220 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11736 | 0.410 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1149 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 9277 | 0.350 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1894 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 3593 | 0.330 |
Why?
|
| Mouth Neoplasms | 1 | 2014 | 596 | 0.320 |
Why?
|
| Carcinoma | 1 | 2019 | 2327 | 0.280 |
Why?
|
| Brazil | 3 | 2019 | 1228 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4020 | 0.270 |
Why?
|
| Neoplasm Staging | 11 | 2022 | 11116 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 697 | 0.220 |
Why?
|
| Conization | 1 | 2021 | 17 | 0.190 |
Why?
|
| Lymphocele | 1 | 2020 | 18 | 0.180 |
Why?
|
| Prognosis | 7 | 2022 | 29600 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2018 | 53 | 0.160 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 263 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 276 | 0.150 |
Why?
|
| Survival Rate | 4 | 2016 | 12719 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 2827 | 0.150 |
Why?
|
| Retreatment | 1 | 2019 | 596 | 0.140 |
Why?
|
| Retrospective Studies | 12 | 2023 | 80566 | 0.140 |
Why?
|
| Myometrium | 1 | 2017 | 174 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2017 | 23972 | 0.130 |
Why?
|
| Ovary | 1 | 2020 | 959 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8516 | 0.120 |
Why?
|
| Female | 20 | 2024 | 392148 | 0.120 |
Why?
|
| Middle Aged | 13 | 2021 | 220584 | 0.120 |
Why?
|
| Aged | 11 | 2021 | 169042 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 571 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2015 | 517 | 0.120 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2017 | 284 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 58894 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 39063 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3461 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 12447 | 0.100 |
Why?
|
| Heterozygote | 1 | 2019 | 2780 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 417 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3514 | 0.090 |
Why?
|
| Adult | 11 | 2021 | 220969 | 0.090 |
Why?
|
| Carboplatin | 1 | 2014 | 793 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 4110 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1852 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 2020 | 0.090 |
Why?
|
| Humans | 20 | 2024 | 760617 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2014 | 1642 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4642 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6474 | 0.070 |
Why?
|
| Cisplatin | 1 | 2014 | 1650 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2019 | 10073 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2019 | 3533 | 0.060 |
Why?
|
| Patient Selection | 1 | 2017 | 4237 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6807 | 0.060 |
Why?
|
| Receptor, erbB-3 | 1 | 2021 | 143 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 74115 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17878 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 11069 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 42188 | 0.030 |
Why?
|
| United States | 1 | 2024 | 72272 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 412 | 0.030 |
Why?
|
| Male | 3 | 2018 | 360358 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 2008 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2650 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20988 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2553 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9311 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 6483 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 59179 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 29868 | 0.010 |
Why?
|